Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Medtronic
Fish and Richardson
Boehringer Ingelheim
Covington
Daiichi Sankyo
Healthtrust
US Army
Argus Health

Generated: June 24, 2018

DrugPatentWatch Database Preview

BOEHRINGER INGELHEIM Company Profile

« Back to Dashboard

What is the competitive landscape for BOEHRINGER INGELHEIM, and what generic alternatives to BOEHRINGER INGELHEIM drugs are available?

BOEHRINGER INGELHEIM has forty-nine approved drugs.

There are ninety US patents protecting BOEHRINGER INGELHEIM drugs. There is one tentative approval on BOEHRINGER INGELHEIM drugs.

There are two thousand two hundred and eighty-four patent family members on BOEHRINGER INGELHEIM drugs in sixty-seven countries and one hundred and sixty-seven supplementary protection certificates in fifteen countries.

Drugs and US Patents for BOEHRINGER INGELHEIM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim MIRAPEX ER pramipexole dihydrochloride TABLET, EXTENDED RELEASE;ORAL 022421-005 Feb 19, 2010 AB RX Yes No 8,679,533 ➤ Try a Free Trial Y ➤ Try a Free Trial
Boehringer Ingelheim MIRAPEX ER pramipexole dihydrochloride TABLET, EXTENDED RELEASE;ORAL 022421-002 Feb 19, 2010 AB RX Yes No 7,695,734 ➤ Try a Free Trial Y ➤ Try a Free Trial
Boehringer Ingelheim AGGRENOX aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 020884-001 Nov 22, 1999 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim FLOMAX tamsulosin hydrochloride CAPSULE;ORAL 020579-001 Apr 15, 1997 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for BOEHRINGER INGELHEIM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim CATAPRES clonidine hydrochloride TABLET;ORAL 017407-001 Approved Prior to Jan 1, 1982 3,454,701 ➤ Try a Free Trial
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004 5,683,677 ➤ Try a Free Trial
Boehringer Ingelheim SPIRIVA RESPIMAT tiotropium bromide SPRAY, METERED;INHALATION 021936-001 Sep 24, 2014 6,726,124*PED ➤ Try a Free Trial
Boehringer Ingelheim TWYNSTA amlodipine besylate; telmisartan TABLET;ORAL 022401-002 Oct 16, 2009 5,591,762 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules eq. to 110 mg base ➤ Subscribe 2015-12-15
➤ Subscribe Extended-release Capsules 25 mg and 200 mg ➤ Subscribe 2007-02-01
➤ Subscribe Extended-releaseTablets 2.5 mg/1000 mg 5 mg/1000 mg ➤ Subscribe 2018-03-28
➤ Subscribe Tablets 0.25 mg ➤ Subscribe 2005-05-27
➤ Subscribe Capsules 0.4 mg ➤ Subscribe 2004-12-20
➤ Subscribe Tablets 80 mg/12.5 mg and 40 mg/12.5 mg ➤ Subscribe 2008-12-31
➤ Subscribe Oral Suspension 7.5 mg/5 mL ➤ Subscribe 2009-12-17
➤ Subscribe Extended-release Tablets 2.25 mg and 3.75 mg ➤ Subscribe 2011-07-26
➤ Subscribe Capsules eq. to 75 mg base and 150 mg base ➤ Subscribe 2014-10-20
➤ Subscribe Tablets 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg ➤ Subscribe 2015-05-04
➤ Subscribe Tablets 20 mg, 30 mg and 40 mg ➤ Subscribe 2017-07-12
➤ Subscribe Tablets 0.125 mg, 0.5 mg, 1 mg and 1.5 mg ➤ Subscribe 2005-06-24
➤ Subscribe Tablets 0.75 mg ➤ Subscribe 2008-07-31
➤ Subscribe Tablets 20 mg, 40 mg and 80 mg ➤ Subscribe 2006-12-26
➤ Subscribe Tablets 80 mg/25 mg ➤ Subscribe 2009-02-27
➤ Subscribe Extended-release Tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg ➤ Subscribe 2010-06-01
➤ Subscribe Extended-release Tablets 400 mg ➤ Subscribe 2013-06-21
➤ Subscribe Tablets 5 mg ➤ Subscribe 2015-05-04

Non-Orange Book US Patents for BOEHRINGER INGELHEIM

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,710,055 Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions ➤ Try a Free Trial
8,486,398 Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds ➤ Try a Free Trial
8,404,697 Quinazoline derivatives for the treatment of cancer diseases ➤ Try a Free Trial
9,044,424 Methods of regulating glucose metabolism, and reagents related thereto ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for BOEHRINGER INGELHEIM Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90016-1 Sweden ➤ Try a Free Trial PRODUCT NAME: OLODATEROL, INDIVIDUELLA OPTISKA ISOMERER DAERAV, BLANDNINGAR AV DE SEPARATA ENANTIOMERERNA ELLER RACEMATEN DAERAV, SYRA ADDITIONSSALTER DAERAV MED FARMAKOLOGISKT GODTAGBARA SYROR SAVAEL SOM SOLVATER OCH/ELLER HYDRATER DAERAV, SAERSKILT OLODATEROL OCH OLODATEROLHYDROKLORID; NAT. REG. NO/DATE: MT-NR 48116 20131114; FIRST REG.: MT MA 211/00401 20130918
07C/043 Belgium ➤ Try a Free Trial PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
437 Luxembourg ➤ Try a Free Trial 91437, EXPIRES: 20230216
2013 Austria ➤ Try a Free Trial PRODUCT NAME: DIBIGATRANEXILAT (MESYLAT); REGISTRATION NO/DATE: EU/1/08/442/001-008 20080318
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
UBS
Johnson and Johnson
Julphar
Citi
QuintilesIMS
Queensland Health
Healthtrust
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.